Immutep to Present Pivotal TACTI-004 Trial in Progress Poster at the European Lung Cancer Congress 2025

Core Insights - Immutep Limited is set to present a poster on the pivotal TACTI-004 Phase III trial at the European Lung Cancer Congress (ELCC) 2025, highlighting its focus on immunotherapy for cancer treatment [1][2] Group 1: Trial Overview - The TACTI-004 Phase III trial evaluates Immutep's MHC Class II agonist, eftilagimod alfa (efti), in combination with Merck's anti-PD-1 KEYTRUDA® and chemotherapy for first-line treatment of advanced or metastatic non-small cell lung cancer (1L NSCLC) [2][3] - The global trial aims to enroll approximately 750 patients across over 150 clinical sites in more than 25 countries, regardless of PD-L1 expression [2] Group 2: Presentation Details - The poster presentation is titled "TACTI-004: a double-blinded, randomized phase 3 trial in patients with advanced/metastatic non-small cell cancer receiving eftilagimod alfa (MHC class II agonist) in combination with pembrolizumab (P) and chemotherapy (C) versus placebo + P + C" [4] - The presentation is scheduled for March 26, 2025, at 13:50 CET, with the poster to be made available on Immutep's website following the event [4] Group 3: Eftilagimod Alfa (efti) Profile - Efti is a proprietary soluble LAG-3 protein and MHC Class II agonist that stimulates both innate and adaptive immunity, enhancing the immune response against cancer [5][6] - Efti is under evaluation for various solid tumors, including NSCLC, head and neck squamous cell carcinoma, and metastatic breast cancer, and has received Fast Track designation from the FDA for first-line treatments in HNSCC and NSCLC [6] Group 4: Company Background - Immutep is a late-stage biotechnology company focused on developing novel immunotherapies for cancer and autoimmune diseases, leveraging its expertise in Lymphocyte Activation Gene-3 (LAG-3) [7] - The company aims to provide innovative treatment options while maximizing shareholder value [7]